Mark J. Vignola - Net Worth and Insider Trading

Mark J. Vignola Net Worth

The estimated net worth of Mark J. Vignola is at least $540,607 dollars as of 2024-12-27. Mark J. Vignola is the CFO of Terns Pharmaceuticals Inc and owns about 91,940 shares of Terns Pharmaceuticals Inc (TERN) stock worth over $540,607. Details can be seen in Mark J. Vignola's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark J. Vignola has not made any transactions after 2024-09-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Mark J. Vignola

To

Mark J. Vignola Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mark J. Vignola owns 2 companies in total, including Applied Therapeutics Inc (APLT) , and Terns Pharmaceuticals Inc (TERN) .

Click here to see the complete history of Mark J. Vignola’s form 4 insider trades.

Insider Ownership Summary of Mark J. Vignola

Ticker Comapny Transaction Date Type of Owner
APLT Applied Therapeutics Inc 2019-05-13 Chief Financial Officer
TERN Terns Pharmaceuticals Inc 2024-09-10 Chief Financial Officer

Mark J. Vignola Latest Holdings Summary

Mark J. Vignola currently owns a total of 1 stock. Mark J. Vignola owns 91,940 shares of Terns Pharmaceuticals Inc (TERN) as of September 10, 2024, with a value of $540,607.

Latest Holdings of Mark J. Vignola

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TERN Terns Pharmaceuticals Inc 2024-09-10 91,940 5.88 540,607

Holding Weightings of Mark J. Vignola


Mark J. Vignola Form 4 Trading Tracker

According to the SEC Form 4 filings, Mark J. Vignola has made a total of 6 transactions in Terns Pharmaceuticals Inc (TERN) over the past 5 years, including 5 buys and 1 sells. The most-recent trade in Terns Pharmaceuticals Inc is the sale of 10,000 shares on September 10, 2024, which brought Mark J. Vignola around $110,000.

Insider Trading History of Mark J. Vignola

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mark J. Vignola Trading Performance

GuruFocus tracks the stock performance after each of Mark J. Vignola's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark J. Vignola is 38.97%. GuruFocus also compares Mark J. Vignola's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark J. Vignola within 3 months outperforms 4 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mark J. Vignola's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mark J. Vignola

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
2 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 25.76 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 25.5 LIMIT LIMIT LIMIT LIMIT LIMIT

Mark J. Vignola Ownership Network

Ownership Network List of Mark J. Vignola

No Data

Ownership Network Relation of Mark J. Vignola

Insider Network Chart

Mark J. Vignola Owned Company Details

What does Applied Therapeutics Inc do?

Who are the key executives at Applied Therapeutics Inc?

Mark J. Vignola is the Chief Financial Officer of Applied Therapeutics Inc. Other key executives at Applied Therapeutics Inc include Chief Medical Officer Riccardo Perfetti , director & 10 percent owner & President and CEO Shoshana Shendelman , and 10 percent owner Alexandria Real Estate Equities, Inc. .

Applied Therapeutics Inc (APLT) Insider Trades Summary

Over the past 18 months, Mark J. Vignola made no insider transaction in Applied Therapeutics Inc (APLT). Other recent insider transactions involving Applied Therapeutics Inc (APLT) include a net sale of 1,276,982 shares made by Shoshana Shendelman , a net sale of 168,003 shares made by Riccardo Perfetti , and a net sale of 875,000 shares made by Alexandria Real Estate Equities, Inc. .

In summary, during the past 3 months, insiders sold 0 shares of Applied Therapeutics Inc (APLT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,438,778 shares of Applied Therapeutics Inc (APLT) were sold and 30,000 shares were bought by its insiders, resulting in a net sale of 2,408,778 shares.

Applied Therapeutics Inc (APLT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Applied Therapeutics Inc Insider Transactions

No Available Data

Mark J. Vignola Mailing Address

Above is the net worth, insider trading, and ownership report for Mark J. Vignola. You might contact Mark J. Vignola via mailing address: C/o Applied Therapeutics, Inc., 340 Madison Avenue, 19th Floor, New York Ny 10173.

Discussions on Mark J. Vignola

No discussions yet.